Bausch Health posts results of Phase 3 rifaximin SSD study in cirrhosis
The study, completed in February 2026, enrolled 517 participants and evaluated rifaximin SSD-40mg IR for delaying the first episode of overt hepatic encephalopathy in patients with liver cirrhosis. Results were first posted on ClinicalTrials.gov on October 28, 2026.
Primary source
ClinicalTrials.gov results record, October 28, 2026
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Read the source: Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation